Luciferase Reporter Cell Line - LOVO

The LoVo cell line was originally established in 1971 from a metastatic tumor nodule resected from the left supraclavicular region of a 56-year-old Caucasian male diagnosed with grade IV Dukes C colon adenocarcinoma. These cells exhibit epithelial morphology with adherent growth and are known to produce carcinoembryonic antigen (CEA). The line carries a KRAS G13D mutation and displays a microsatellite instability-high (MSI-H) phenotype, along with mutations in APC, TGFBR2, and other genes commonly altered in colorectal cancer. The Luciferase Reporter Cell Line - LOVO is derived from this parental line through stable integration of a firefly luciferase expression construct, enabling real-time bioluminescent detection both in vitro and in vivo. The luciferase signal correlates linearly with viable cell number, making it suitable for longitudinal monitoring without the need for repeated cell harvest or invasive sampling.

This reporter cell line supports a broad range of applications in colorectal cancer research. It is frequently employed in subcutaneous and orthotopic xenograft models to non-invasively track tumor growth, metastatic dissemination, and response to therapeutic interventions using bioluminescence imaging. In cell-based studies, the line is used for dual-luciferase reporter assays to investigate promoter activity, miRNA targeting, and signaling pathway modulation. It also serves as a tool for high-throughput screening of candidate anticancer compounds, where luciferase readouts can be coupled with viability or cytotoxicity endpoints. Because the parental LoVo line carries clinically relevant mutations such as KRAS G13D and is MSI-H, the reporter version offers a more translationally relevant system for evaluating drug efficacy in the context of these genetic backgrounds.